- Home
- TSI vs PRQR Comparison
TSI vs PRQR Comparison
Compare TSI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | PRQR |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 244.1M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TSI | PRQR |
|---|---|---|
| Price | $4.40 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 154.3K | ★ 863.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $1.33 |
| 52 Week High | $5.06 | $3.10 |
Technical Indicators
Market Signals| Indicator | TSI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 58.12 |
| Support Level | N/A | $1.37 |
| Resistance Level | $4.46 | $1.99 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 70.59 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.